Patents by Inventor Martha Heider St. Clair

Martha Heider St. Clair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV
    Patent number: 6544961
    Abstract: The present invention relates to therapeutic combinations of 3S-[3R*(1R*,2S*)-[3 -[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester (141W94), 3′-azido-3′-deoxythymidine (zidovudine) and (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (FTC) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: April 8, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Martha Heider St. Clair, David Walter Barry
  • Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
    Patent number: 6486136
    Abstract: The present invention relates to therapeutic combinations of [3R*(1R*,2S*)]-[3[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester (141W94), 3′-azido-3′-deoxythymidine (zidovudine) and (1S,4R)-cis-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: November 26, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Martha Heider St. Clair, David Walter Barry
  • Synergistic combinations of zidovudine, 1592U89 and 3TC
    Patent number: 6417191
    Abstract: The present invention relates to therapeutic combinations of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol (1592U89), 3′-azido-3′-deoxythymidine (zidovudine) and (2R,cis)-4-amino-]-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (FTC)) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: July 9, 2002
    Assignee: GlaxoSmithKline
    Inventors: David Walter Barry, Martha Heider St. Clair
  • Treatment of HTLV-I infections
    Patent number: 5885957
    Abstract: Treatment of animals or humans carrying or infected with HTLV-I, HTLV-I (including HTLV-I-associated leukemias or lymphomas), non-A, non-B hepatitis virus, hepatitis B virus, EBV, equine infectious anaemia or other lentiviruses or having antibodies to said viruses is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: March 23, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
  • Treatment of human viral infections
    Patent number: 5877163
    Abstract: A method of treating AIDS with 3'-azido-3'-deoxythymidine in combination with interleukin II or phosphonoformate is presented.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: March 2, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
  • Treatment of human viral infections
    Patent number: 5683990
    Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose. Additionally, there is disclosed the treatment of Kaposi's sarcoma with 3'-azido-3'-deoxythymidine (AZT) and the synergistic activity in the treatment of humans infected with HTLV-III of AZT and interferon as well as AZT and acyclovir and AZT and 2-amino-9-(2-hydroxyethoxymethyl)purine or an ester thereof.
    Type: Grant
    Filed: August 21, 1986
    Date of Patent: November 4, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
  • Treatment of viral infections
    Patent number: 5643891
    Abstract: Treatment of animals or humans carrying or infected with HTLV-I, HTLV-I (including HTLV-I-associated leukemias or lymphomas), non-A, non-B hepatitis virus, hepatitis B virus, EBV, equine infectious anaemia or other lentiviruses or having antibodies to said viruses is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
    Type: Grant
    Filed: February 26, 1993
    Date of Patent: July 1, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman